Back to list

Patricia Lievens

Affiliated Researcher

Former colleague

Research Line

Neurobiology of miRNA

Contacts

About

Patricia M.-J. Lievens

 

Role: Postdoctoral fellow

 

Platform: Neuroscience and Brain Technologies

 

E-mail: patricia.lievens@iit.it

 

Patricia Lievens graduated with honours in Biological Sciences at the University of Siena (Italy) in 1989. From 1990 to 1992 she conducted a research on transcription factors involved in myeloid differentiation supervised by Stuart Orkin, in the Department of Pediatric Oncology of Children’s Hospital at the Harvard Medical School of Boston (USA). Here she learned the basics of molecular biology and contributed to the cloning of the transcriptional repressor CCAAT Displacement protein (CDP). Back to Italy she pursued her studies until 1994 in the laboratory of Sergio Ottolenghi, in the Division of Human Genetics at the University of Milano. In 1995 she obtained a research contract at the Neurological Institute “C. Besta” of Milano to work on prion protein (PrP) diseases under the supervision of Fabrizio Tagliavini. Here she studied the genetic Gestmann-Sträussler-Sheinker disease, mainly contributing to the characterization of the biochemical properties and composition of PrP amyloid structures. In 2001 she moved to the University of Verona where she started a new project on Fibroblast Growth Factor Receptors (FGFRs) focusing on cellular and biochemical changes associated with mutated forms of FGFRs causing chondrodysplasias. The research was carried out with Elio Liboi in the Division of Biochemistry of the Department of Morphological and Biomedical Sciences. In 2007 she accomplished her PhD in Biology and Molecular and Cellular Pathology with a thesis on the characterization of the early secretory pathway of FGFRs biosynthesis.

Currently, she is a postdoctotal fellow at the Italian Institute of Technology (IIT) working with Alexander Dityatev on projects addressing the role of FGFRs and palmitoylation in neuronal plasticity and designing molecular tools to control adhesive interactions between neurons.

Patricia Lievens has a strong experimental background in molecular and cellular biology and biochemical techniques.

Selected Publications

SELECTED PUBLICATIONS

 

 

- Kochlamazashvili G, Henneberger C, Bukalo O, Dvoretskova E, Senkov O, Lievens P. M-J., Westenbroek R, Engel AK, Catterall WA, Rusakov DA, Schachner M, Dityatev A. The extracellular matrix molecule hyaluronic acid regulates hippocampal synaptic plasticity by modulating postsynaptic L-type Ca(2+) channels. Neuron 67, 116-128 (2010)

- Lievens P. M.-J., Zanolli E., Garofalo S., and Liboi E.. Cell adaptation to activated FGFR3 includes Sprouty4 up regulation to inhibit the receptor-mediated ERKs activation from the endoplasmic reticulum. FEBS Lett. 583, 3254-3258 (2009)

- Lievens P. M.-J., De Servi B., Garofalo S., Lunstrum G. P., Horton W.A. and  Liboi E.. Transient dimerization and interaction with ERGIC-53 occur in the fibroblast growth factor receptor 3 early secretory pathway. Int. J. of Biochem. & Cell Biol. 40, 2649-59 (2008)

- Lievens P. M.-.J., Roncador A. and Liboi E. K644E/M FGFR3 mutants activate Erk1/2 from the Endoplasmic Reticulum through FRS2a and PLCg-independent pathways. J. Mol. Biol. 357, 783-792 (2006)

- Lievens P. M.-J., Mutinelli C., Baynes D. and Liboi E. The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling. J. Biol. Chem. 279, 43254-43260 (2004).

- Lievens P. M.-J. and Liboi E. The thanatophoric dysplasia type II mutation hampers complete maturation of FGF receptor 3, which activates STAT1 from the endoplasmic reticulum. J. Biol. Chem. 278, 17344-17349 (2003).

- Tagliavini F., Lievens P. M.-J., Trinchant C., Warter J.M., Mohr M., Perini F., Salmona M., Rossi G., Giaccone G., Piccardo P., Ghetti B., Bugiani O., Beavis R.C., Frangione B., Prelli F. N- and C-Terminal fragments of the Prion Protein participate in amyloid formation in Gerstmann-Sträussler-Scheinker disease with Ala to Val substitution at codon 117 (Alsatian family). J. Biol. Chem. 276, 6009-6015 (2001).

- Piccardo P., Dlouhy S. R., Lievens P. M.-J., Young K., Bird T. D, Nochlin D, Dickson D.W, Vinters H. V., Zimmermann T.R., Mackenzie I. R, Kish S. J, Ang L. C., De Carli C.,Pocchiari M., Brown P., Gibbs C. Jr., Gajdusek D.C., Bugiani O., Tagliavini F. and Ghetti B. Phenotypic varability of Gerstmann-Sträussler-Scheinker disease associated with prion protein heterogeneity. J. Neuropathol. Exp. Neurol. 57, 979-988 (1998).

- Jiménez-Huete A., Lievens P. M.-J., Vidal R., Piccardo P., Ghetti B., Tagliavini F., Frangione B. and Prelli F. Endogenous proteolytic cleavage of normal and disease-associated isoforms of the human prion protein in neurol and non-neural tissues. Am. J. Pathol. 153, 1561-1572 (1998).

- Tagliavini F., McArthur R. A., Canciani B., Giaccone G., Porro M., Bugiani M., Lievens P. M.-J., Bugiani O., Peri E., Dall'Ara P., Rocchi M., Poli G., Forloni G., Bandiera T., Varasi M., Suarato A., Cassutti P., Cervini M.A., Lansen J., Salmona M. and Post C. Effectiveness of anthracyclines against experimental prion disease in syrian hamsters. Science 276, 1119-1122 (1997).

- Lievens P. M.-J., Donady J. J., Tufarelli C. and Neufeld E. J. Repressor activity of CCAAT Displacement protein in HL-60 myeloid leukemia cells. J. Biol. Chem. 270, 12745-12750 (1995).

- Neufeld E.J., Skalnik D.G., Lievens P. M.-J., Orkin S.H. Human CCAAT displacement protein, a repressor of developmentally-regulated gene expression, is the homolog of the Drosophila homeodomain protein, Cut. Nature Genetics 1, 50-55 (1992).

INFORMATION NOTICE ON COOKIES

IIT's website uses the following types of cookies: browsing/session, analytics, functional and third party cookies. Users can choose whether or not to accept the use of cookies and access the website.
By clicking on further information, the full information notice on the types of cookies used will be displayed and you will be able to choose whether or not to accept cookies whilst browsing on the website.
Further information
Accept and close

I numeri di IIT

L’Istituto Italiano di Tecnologia (IIT) è una fondazione di diritto privato - cfr. determinazione Corte dei Conti 23/2015 “IIT è una fondazione da inquadrare fra gli organismi di diritto pubblico con la scelta di un modello di organizzazione di diritto privato per rispondere all’esigenza di assicurare procedure più snelle nella selezione non solo nell’ambito nazionale dei collaboratori, scienziati e ricercatori ”.

IIT è sotto la vigilanza del Ministero dell'Istruzione, dell'Università e della Ricerca e del Ministero dell'Economia e delle Finanze ed è stato istituito con la Legge 326/2003. La Fondazione ha l'obiettivo di promuovere l'eccellenza nella ricerca di base e in quella applicata e di favorire lo sviluppo del sistema economico nazionale. La costruzione dei laboratori iniziata nel 2006 si è conclusa nel 2009.

Lo staff complessivo di IIT conta circa 1440 persone. L’area scientifica è rappresentata da circa l’85% del personale. Il 45% dei ricercatori proviene dall’estero: di questi, il 29% è costituito da stranieri provenienti da oltre 50 Paesi e il 16% da italiani rientrati. Oggi il personale scientifico è composto da circa 60 principal investigators, circa 110 ricercatori e tecnologi di staff, circa 350 post doc, circa 500 studenti di dottorato e borsisti, circa 130 tecnici. Oltre 330 posti su 1400 creati su fondi esterni. Età media 34 anni. 41% donne / 59 % uomini.

Nel 2015 IIT ha ricevuto finanziamenti pubblici per circa 96 milioni di euro (80% del budget), conseguendo fondi esterni per 22 milioni di euro (20% budget) provenienti da 18 progetti europei17 finanziamenti da istituzioni nazionali e internazionali, circa 60 progetti industriali

La produzione di IIT ad oggi vanta circa 6990 pubblicazioni, oltre 130 finanziamenti Europei e 11 ERC, più di 350 domande di brevetto attive, oltre 12 start up costituite e altrettante in fase di lancio. Dal 2009 l’attività scientifica è stata ulteriormente rafforzata con la creazione di dieci centri di ricerca nel territorio nazionale (a Torino, Milano, Trento, Parma, Roma, Pisa, Napoli, Lecce, Ferrara) e internazionale (MIT ed Harvard negli USA) che, unitamente al Laboratorio Centrale di Genova, sviluppano i programmi di ricerca del piano scientifico 2015-2017.

IIT: the numbers

Istituto Italiano di Tecnologia (IIT) is a public research institute that adopts the organizational model of a private law foundation. IIT is overseen by Ministero dell'Istruzione, dell'Università e della Ricerca and Ministero dell'Economia e delle Finanze (the Italian Ministries of Education, Economy and Finance).  The Institute was set up according to Italian law 326/2003 with the objective of promoting excellence in basic and applied research andfostering Italy’s economic development. Construction of the Laboratories started in 2006 and finished in 2009.

IIT has an overall staff of about 1,440 people. The scientific staff covers about 85% of the total. Out of 45% of researchers coming from abroad 29% are foreigners coming from more than 50 countries and 16% are returned Italians. The scientific staff currently consists of approximately 60 Principal Investigators110 researchers and technologists350 post-docs and 500 PhD students and grant holders and 130 technicians. External funding has allowed the creation of more than 330 positions . The average age is 34 and the gender balance proportion  is 41% female against 59% male.

In 2015 IIT received 96 million euros in public funding (accounting for 80% of its budget) and obtained 22 million euros in external funding (accounting for 20% of its budget). External funding comes from 18 European Projects, other 17 national and international competitive projects and approximately 60 industrial projects.

So far IIT accounts for: about 6990 publications, more than 130 European grants and 11 ERC grants, more than 350 patents or patent applications12 up start-ups and as many  which are about to be launched. The Institute’s scientific activity has been further strengthened since 2009 with the establishment of 11 research nodes throughout Italy (Torino, Milano, Trento, Parma, Roma, Pisa, Napoli, Lecce, Ferrara) and abroad (MIT and Harvard University, USA), which, along with the Genoa-based Central Lab, implement the research programs included in the 2015-2017 Strategic Plan.